Benaim E, Sorrentino B P
Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.
Invest New Drugs. 1996;14(1):87-99. doi: 10.1007/BF00173685.
An increased understanding of the molecular mechanisms of cancer and the ability to introduce exogenous genes into mammalian cells has led to the development of oncologic treatment strategies based upon gene transfer. Preclinical animal models have suggested a variety of approaches which are now being tested in pediatric trials. Studies using marker genes to trace cell origin have already generated important information regarding autologous bone marrow transplantation for pediatric cancers. A variety of therapeutic genes are also being clinically tested. Trials are underway to determine if introduction of immunostimulatory genes into cancer cells can be used to enhance host antitumor immunity. Treatment of primary brain tumors with insertion of drug sensitization genes is a promising new therapy that is also being clinically evaluated. Other strategies such as insertion of drug resistance genes into hematopoietic cells, anti-oncogene therapy, and tumor suppressor gene replacement are being tested in adults and may find use in pediatric cancer treatment. Although gene transfer offers promising new approaches for the therapy of pediatric cancer, many technical problems remain which limit efficacy and widespread use. Further basic research in the molecular biology of cancer and in vector development will be required to realize the full potential of gene therapy strategies.
对癌症分子机制的深入了解以及将外源基因导入哺乳动物细胞的能力,促使了基于基因转移的肿瘤治疗策略的发展。临床前动物模型已提出多种方法,目前正在儿科试验中进行测试。使用标记基因追踪细胞起源的研究已经产生了关于小儿癌症自体骨髓移植的重要信息。多种治疗性基因也正在进行临床试验。正在进行试验以确定将免疫刺激基因导入癌细胞是否可用于增强宿主抗肿瘤免疫力。插入药物敏感基因治疗原发性脑肿瘤是一种有前景的新疗法,也正在进行临床评估。其他策略,如将耐药基因插入造血细胞、抗癌基因治疗和肿瘤抑制基因替代,正在成人中进行测试,可能会用于小儿癌症治疗。尽管基因转移为小儿癌症治疗提供了有前景的新方法,但仍存在许多技术问题限制了其疗效和广泛应用。要充分发挥基因治疗策略的潜力,还需要在癌症分子生物学和载体开发方面进行进一步的基础研究。